Sanofi has become the latest big pharma company to boost manufacturing in the US with a hefty investment as the biopharma industry safeguards itself against the continued threat of pharma tariffs ...

Sanofi has returned to Nurix Therapeutics for another autoimmune candidate, paying $15 million and committing up to $465 million for exclusive rights to a degrader of a once-undruggable ...

I'll start by comparing the revenue growth rates of AbbVie and Sanofi, then move on to discuss how often these two leaders in the autoimmune disease treatment market beat Wall Street analysts ...

Sanofi is joining its fellow drugmakers in trying to put new restrictions on savings sent to hospitals in a federal drug discount program. A spokesperson for Sanofi confirmed plans to implement a ...

PARIS (Reuters) -Sanofi on Sunday reached an agreement on terms to sell a controlling stake in its consumer health unit Opella to U.S. private equity firm Clayton Dubilier & Rice (CD&R), French ...

Genentech and Hinge Health cut portions of their Bay Area workforces, while Sanofi and Abbott Laboratories announced major facilities closures. All told, 807 people will lose their jobs.

As Sanofi strives to become a global immunology leader, it's also busy making the most of a crucial immunization rollout with partner AstraZeneca. On both fronts, Sanofi expects to see dividends ...

Sanofi is buying Inhibrx in a $1.7 billion deal as the French pharmaceutical giant expands its pipeline of drugs that can treat rare diseases. The agreement will give Sanofi access to Inhibrx's ...

Sanofi has reported setbacks to a trio of candidates bought in by its business development team, halting (PDF) work or posting negative data on assets picked up from Denali Therapeutics, Kymab and ...

We have just scratched the surface as to how we embrace these disruptive technologies to achieve our ambition of transforming the practice of medicine”, Paul Hudson, CEO of Sanofi. In under two ...

Sanofi is rolling out its artificial intelligence app, Plai, as it doubles down on its efforts to incorporate AI throughout its research and development activities. The app, developed in partnership ...

Sanofi is reducing the price of its most important insulin product. A pending acquisition could help pick up the slack in diabetes care. Sanofi's business extends beyond its diabetes-related ...